Angina pectoris is a clinical indication characterized by precordial heaviness or discomfort due to transient myocardial ischemia without infarction, elicited by physical exertion or psychological stress. Angina pectoris is categorized as - stable, unstable, microvascular and Prinzmetal / variant. Angina pectoris is an initial presentation of coronary heart disease (CHD) and exerts a major impact on quality of life (QOL), costs to the society and ability to work.
This report contains market size and forecasts of Angina Pectoris Drugs in Global, including the following market information:
- Global Angina Pectoris Drugs Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Angina Pectoris Drugs market was valued at 8865.7 million in 2021 and is projected to reach US$ 12640 million by 2028, at a CAGR of 5.2% during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Beta Blockers Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Angina Pectoris Drugs include Pfizer, Bayer, AstraZeneca, Gilead, Novartis, GlaxoSmithKline, Merck, Mylan and Teva Pharmaceutical. etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Angina Pectoris Drugs companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Angina Pectoris Drugs Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Angina Pectoris Drugs Market Segment Percentages, by Type, 2021 (%)
- Beta Blockers
- Calcium Antagonists
- Anticoagulants
- Anti-Platelets
- Others
Global Angina Pectoris Drugs Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Angina Pectoris Drugs Market Segment Percentages, by Application, 2021 (%)
Global Angina Pectoris Drugs Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Angina Pectoris Drugs Market Segment Percentages, By Region and Country, 2021 (%)
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- France
- U.K.
- Italy
- Russia
- Nordic Countries
- Benelux
- Rest of Europe
- Asia
- China
- Japan
- South Korea
- Southeast Asia
- India
- Rest of Asia
- South America
- Brazil
- Argentina
- Rest of South America
- Middle East & Africa
- Turkey
- Israel
- Saudi Arabia
- UAE
- Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
- Key companies Angina Pectoris Drugs revenues in global market, 2017-2022 (estimated), ($ millions)
- Key companies Angina Pectoris Drugs revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
- Pfizer
- Bayer
- AstraZeneca
- Gilead
- Novartis
- GlaxoSmithKline
- Merck
- Mylan
- Teva Pharmaceutical
